



BIOTOSCANA INVESTMENTS S.A.

Corporate Taxpayer's ID (CNPJ/MF): 19.688.956/0001-56
L-1470 Luxembourg, 70 route d'Esch, Grand-Duché de Luxembourg
Legal representative in Brazil: Av. dos Imarés, 401, São Paulo, SP

NOTICE TO THE MARKET
CLARIFICATIONS ON PRESS RELEASE

B3 S.A. – Brasil, Bolsa, Balcão
Ana Lucia da Costa Pereira
Listing and Issuers Supervision Department

c.c.: CVM – Comissão de Valores Mobiliários
Sr. Fernando Soares Vieira – Investor Relations Supervision
Sr. Francisco José Bastos Santos –Market Relations and Intermediaries Supervision

Re: Notice 907/2019-SLS
Request for clarifications on press release

Dear Sirs,

BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, hereby provides clarification, as requested in Notice 907/2019-SLS– sent by B3 S.A. – Brasil, Bolsa, Balcão, of a note published today in the media regarding the potential sale of control of the Company, transcribed below:

*“October 07, 2019
907/2019-SLS*

*Biotoscana Investments S.A.
At. Mr. Claudio Coracini
Investor Relations Officer*

Re.: Request for clarification on news in the media

Dear Sirs,

The note published by Agência Estado – Broadcast on 10/072019, under the title “Biotoscana is disputed by Eurofarma and Knight Therapeutics”, includes, among other information:

1. *Advent and Essex would be in advanced conversations regarding the sale of Biotoscana's control;*
2. *Eurofarma and the canadian company Knight Therapeutics would have submitted proposals and a decision should be made in the next weeks;*
3. *If the transaction is confirmed, it can trigger a Public Offer for the Acquisition of shares (OPA).*

We request clarification on the items indicated above, by 10/08/2019, confirming or denying their accuracy, as well as other information considered important."

The Company informs that it has consulted its controlling shareholders, and, as mentioned in such news, they confirmed they have been negotiating with certain investors, but no decision related to any possible transaction involving the sale of control with any investor has been concluded to date.

In case a sale of control occurs, a mandatory tender offer will be triggered in accordance with clause 12 of the bylaws of GBT.

The Company reiterates its commitment in maintaining its shareholders and the market in general informed on the progress of any matters that are relevant to the market, in compliance with applicable legislation.

Montevideo, October 7th, 2019

BIOTOSCANA INVESTMENTS S.A.

Claudio Coracini

Legal Representative in Brazil

About GBT Grupo Biotoscana

GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT's strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.